These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30360603)

  • 1. Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy.
    Treenert A; Areepium N; Tanasanvimon S
    Asian Pac J Cancer Prev; 2018 Oct; 19(10):2757-2764. PubMed ID: 30360603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity.
    García Gil S; Ramos Díaz R; Nazco Casariego GJ; Llanos Muñoz M; Viña Romero MM; Martín Calero B; Pérez Pérez JA; Gutiérrez Nicolás F
    Med Clin (Barc); 2018 Dec; 151(11):425-430. PubMed ID: 29499902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
    Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.
    Huang L; Zhang T; Xie C; Liao X; Yu Q; Feng J; Ma H; Dai J; Li M; Chen J; Zang A; Wang Q; Ge S; Qin K; Cai J; Yuan X
    PLoS One; 2013; 8(10):e77223. PubMed ID: 24143213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
    Di Martino MT; Arbitrio M; Leone E; Guzzi PH; Rotundo MS; Ciliberto D; Tomaino V; Fabiani F; Talarico D; Sperlongano P; Doldo P; Cannataro M; Caraglia M; Tassone P; Tagliaferri P
    Cancer Biol Ther; 2011 Nov; 12(9):780-7. PubMed ID: 21892003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.
    Teft WA; Welch S; Lenehan J; Parfitt J; Choi YH; Winquist E; Kim RB
    Br J Cancer; 2015 Mar; 112(5):857-65. PubMed ID: 25611302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
    Kaewboonlert N; Thitisopee W; Sirintronsopon W; Porntadavity S; Jeenduang N
    J Clin Pharm Ther; 2018 Oct; 43(5):647-655. PubMed ID: 29575099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine.
    Paulík A; Nekvindová J; Filip S
    Tumori; 2020 Apr; 106(2):87-94. PubMed ID: 30514181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
    Akiyama Y; Fujita K; Ishida H; Sunakawa Y; Yamashita K; Kawara K; Miwa K; Saji S; Sasaki Y
    Drug Metab Pharmacokinet; 2012; 27(3):325-35. PubMed ID: 22201120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer.
    Lampropoulou DI; Aravantinos G; Katifelis H; Lazaris F; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
    Cancer Biomark; 2019; 25(2):213-221. PubMed ID: 31045514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.
    Rhodes KE; Zhang W; Yang D; Press OA; Gordon M; Vallböhmer D; Schultheis AM; Lurje G; Ladner RD; Fazzone W; Iqbal S; Lenz HJ
    Drug Metab Lett; 2007 Jan; 1(1):23-30. PubMed ID: 19356014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.
    Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Cremolini C; Lonardi S; Bergamo F; Ning Y; Yamamoto N; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Stintzing S; Heinemann V; Loupakis F; Falcone A; Lenz HJ
    Pharmacogenomics J; 2018 Sep; 18(5):623-632. PubMed ID: 29925895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer.
    Lampropoulou DI; Aravantinos G; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
    Int J Colorectal Dis; 2019 Nov; 34(11):1871-1877. PubMed ID: 31598748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.
    Oh ES; Kim CO; Cho SK; Park MS; Chung JY
    Drug Metab Pharmacokinet; 2013; 28(3):196-202. PubMed ID: 23007012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.
    Endo S; Fukahori A; Tokuhiro S; Shinagawa A; Walker J; Yoshihara K; Ishizuka H; Ieiri I; Sugiyama Y
    J Hum Genet; 2012 Aug; 57(8):531-44. PubMed ID: 22695893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
    Niemi M; Arnold KA; Backman JT; Pasanen MK; Gödtel-Armbrust U; Wojnowski L; Zanger UM; Neuvonen PJ; Eichelbaum M; Kivistö KT; Lang T
    Pharmacogenet Genomics; 2006 Nov; 16(11):801-8. PubMed ID: 17047488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
    Kim CO; Cho SK; Oh ES; Park MS; Chung JY
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.